Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc. is focused on developing and commercializing therapeutic laser technology and cancer treatments. They are launching an upgraded laser system called the TLC-2000 in Q1 2014 that will provide recurring revenue through monthly treatment fees. This system has been proven effective in clinical studies for pain, inflammation, and other conditions. Theralase also has patented photo dynamic compounds for non-invasive cancer destruction now undergoing preclinical and clinical trials. The company is seeking a $3M private placement to expand their laser center network internationally and in major US cities starting in 2014 to increase sales of their FDA-approved laser technology.
This randomized controlled trial evaluated the effectiveness of low-level laser therapy (LLT) for treating chronic knee pain. 126 patients with knee osteoarthritis were randomly assigned to receive either active laser treatment or sham laser treatment over 12 sessions within 4 weeks. The primary outcome was pain level measured using a visual analog scale (VAS) from 0-10. Results showed that the active laser treatment provided significant pain relief and osteoarthritic improvements compared to the sham laser, with statistical significance of p<0.01 in reduced VAS scores from baseline to 30-day follow-up. The laser treatment was thus found to be an effective adjunctive therapy for chronic knee pain.
More than 350,000 new cases of bladder cancer are diagnosed worldwide each year; the vast majority (> 90%) of these are transitional cell carcinomas (TCC). The most important risk factors for the development of bladder cancer are smoking and occupational exposure to toxic chemicals. Painless visible haematuria is the most common presenting symptom of bladder cancer; significant haematuria requires referral to a specialist urology service. Cystoscopy and urine cytology are currently the recommended tools for diagnosis of bladder cancer. Excluding muscle invasion is an important diagnostic step, as outcomes for patients with muscle invasive TCC are less favourable. For non-muscle invasive bladder cancer, transurethral resection followed by intravesical chemotherapy (
Low Level Laser Therapy (LLLT) is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.
Theralase announced its 2012 year-end financial results, reporting a 10% reduction in total revenue to $1.8 million compared to 2011, primarily due to a decrease in laser sales in the US and internationally. Research and development costs increased 15% to $873,335 as the company focused on developing its next-generation laser and photo dynamic compound cancer destruction technology. The net loss for 2012 was $1.5 million, up from $1.45 million in 2011, due to increases in stock-based compensation and R&D costs. Theralase is preparing to launch its new TLC-2000 laser in 2013 and expects its photo dynamic compound bladder cancer treatment to be ready for human trials in 2014.
Theralase Technologies Inc. is focused on developing and commercializing therapeutic laser technology and cancer treatments. They are launching an upgraded laser system called the TLC-2000 in Q1 2014 that will provide recurring revenue through monthly treatment fees. This system has been proven effective in clinical studies for pain, inflammation, and other conditions. Theralase also has patented photo dynamic compounds for non-invasive cancer destruction now undergoing preclinical and clinical trials. The company is seeking a $3M private placement to expand their laser center network internationally and in major US cities starting in 2014 to increase sales of their FDA-approved laser technology.
This randomized controlled trial evaluated the effectiveness of low-level laser therapy (LLT) for treating chronic knee pain. 126 patients with knee osteoarthritis were randomly assigned to receive either active laser treatment or sham laser treatment over 12 sessions within 4 weeks. The primary outcome was pain level measured using a visual analog scale (VAS) from 0-10. Results showed that the active laser treatment provided significant pain relief and osteoarthritic improvements compared to the sham laser, with statistical significance of p<0.01 in reduced VAS scores from baseline to 30-day follow-up. The laser treatment was thus found to be an effective adjunctive therapy for chronic knee pain.
More than 350,000 new cases of bladder cancer are diagnosed worldwide each year; the vast majority (> 90%) of these are transitional cell carcinomas (TCC). The most important risk factors for the development of bladder cancer are smoking and occupational exposure to toxic chemicals. Painless visible haematuria is the most common presenting symptom of bladder cancer; significant haematuria requires referral to a specialist urology service. Cystoscopy and urine cytology are currently the recommended tools for diagnosis of bladder cancer. Excluding muscle invasion is an important diagnostic step, as outcomes for patients with muscle invasive TCC are less favourable. For non-muscle invasive bladder cancer, transurethral resection followed by intravesical chemotherapy (
Low Level Laser Therapy (LLLT) is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary laser technology.
Theralase announced its 2012 year-end financial results, reporting a 10% reduction in total revenue to $1.8 million compared to 2011, primarily due to a decrease in laser sales in the US and internationally. Research and development costs increased 15% to $873,335 as the company focused on developing its next-generation laser and photo dynamic compound cancer destruction technology. The net loss for 2012 was $1.5 million, up from $1.45 million in 2011, due to increases in stock-based compensation and R&D costs. Theralase is preparing to launch its new TLC-2000 laser in 2013 and expects its photo dynamic compound bladder cancer treatment to be ready for human trials in 2014.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
A case study examines the use of low-level laser therapy (LLT) to treat a patient with traumatic brain injury (TBI) from repeated blows to the head with a lead pipe. The patient experienced severe, daily migraines for two years since the injury. After five 10-minute LLLT treatments over two weeks targeting areas of the scalp and head, the patient's migraine pain was eliminated according to a pain scale. The study suggests LLLT may help address symptoms of TBI through vasodilation and increased blood flow to support metabolic needs in the brain.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. The laser technology safely and effectively treats pain, inflammation, and accelerates healing without side effects. Theralase lasers have been proven in over 3,000 clinical studies to treat various conditions and have helped thousands of practitioners worldwide. The laser system provides a turn-key solution with product, support, training and marketing materials to help practices treat patients and increase revenue.
Theralase designs and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. Their laser systems safely and effectively treat pain, inflammation, and musculoskeletal conditions to accelerate healing. Theralase offers clinical research, training, marketing support, and technical support to help practitioners treat conditions and get equine athletes back in competition more quickly. Studies show Theralase laser therapy can reduce inflammation and pain and speed recovery for injuries like tendon strains, improving outcomes for equine veterinary practices and owners.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in the human, equine, and companion animal markets. Their laser technology is safe and effective for treating pain, inflammation, and other conditions by promoting cellular regeneration and rebalancing sodium-potassium pathways. Over 3,000 clinical studies and testimonials from medical practitioners have proven the effectiveness of Theralase's laser therapy systems.
Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.
Theralase announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of this technology through strategic partnerships to develop sterilization applications using its low-cost and
Theralase Technologies announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of the PDC technology through strategic partnerships for sterilization applications.
This meta-analysis reviewed 22 randomized controlled trials involving 1014 patients to determine the effectiveness of low-level laser therapy (LLLT) for pain relief in various joint areas. The average methodological quality score of the trials was 7.96 out of 10. The analysis found that 11 trials reported positive effects of LLLT for pain relief while 11 reported negative effects. However, when pooling the results, the mean weighted difference in pain reduction on a visual analogue scale was 13.96 mm in favor of the active LLLT groups, indicating LLLT provides statistically significant pain relief for joints. Restricting the analysis to trials using energy doses within previously suggested therapeutic windows produced even greater mean pain relief of 19.88-21
Theralase Technologies Inc. announced a non-brokered private placement to raise up to $500,000 CAD by issuing units consisting of shares and warrants at $0.25 per unit. Proceeds will support small animal cancer trials, research on photodynamic compounds, expansion of laser sales and marketing in the US, and commercialization of a new therapeutic laser. Theralase designs and markets patented superpulsed laser technology for biostimulation, biodestruction, pain treatment, and tissue regeneration in humans and animals.
Theralase Technologies Inc. announced that it has signed an exclusive distribution agreement with Chengdu Disi Industrial Co. Ltd. to distribute Theralase products in mainland China. Under the terms, Chengdu Disi will market, sell, and provide support for Theralase lasers in China, and Theralase will train Chengdu Disi's personnel. Sales estimates for the first year are planned to exceed $1 million USD. The President of Chengdu Disi stated they were impressed by Theralase's technology and are confident they can successfully promote the brand in China.
This randomized, placebo-controlled clinical trial evaluated low-level laser therapy (LLLT) for treating chronic knee pain in 126 patients. Patients received 12 treatments over 4 weeks with a therapeutic laser system or sham laser plus standardized chiropractic techniques. The primary outcome was pain level measured by the visual analog scale (VAS). Results showed significant pain relief and osteoarthritic improvements in the therapeutic laser group compared to the sham laser group, demonstrating LLLT's effectiveness for treating chronic knee pain.
The document is a quarterly newsletter from Theralase providing updates on their two divisions - Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). It discusses upcoming webinars and seminars, corporate updates including the creation of two operating divisions and identification of bladder cancer as the first clinical target for PDT. It also summarizes partnerships, financing activities, and research progress, including the selection of a leading anti-cancer drug candidate and outlining plans for commercialization and growth.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase complies with FDA, Health Canada, CE, ISO-13485 and CSA-601 regulatory approvals to ensure efficacy, safety and quality in manufacture. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. announced its year-end 2011 financial results, reporting stable total revenues of $2,027,058 compared to 2010. Selling expenses increased 55% due to expansion efforts in the US market, while administrative expenses decreased 17%. Research and development costs rose 26% to advance laser and cancer/bacteria destruction technologies. The net loss was $1,453,974 including non-cash expenses, compared to a 2010 net loss of $1,168,350. Subsequent to year-end, Theralase completed a private placement for gross proceeds of $750,000.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com 1-866-843-5273
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
A case study examines the use of low-level laser therapy (LLT) to treat a patient with traumatic brain injury (TBI) from repeated blows to the head with a lead pipe. The patient experienced severe, daily migraines for two years since the injury. After five 10-minute LLLT treatments over two weeks targeting areas of the scalp and head, the patient's migraine pain was eliminated according to a pain scale. The study suggests LLLT may help address symptoms of TBI through vasodilation and increased blood flow to support metabolic needs in the brain.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. The laser technology safely and effectively treats pain, inflammation, and accelerates healing without side effects. Theralase lasers have been proven in over 3,000 clinical studies to treat various conditions and have helped thousands of practitioners worldwide. The laser system provides a turn-key solution with product, support, training and marketing materials to help practices treat patients and increase revenue.
Theralase designs and manufactures patented superpulsed laser technology for biostimulative applications in human, equine, and companion animal medicine. Their laser systems safely and effectively treat pain, inflammation, and musculoskeletal conditions to accelerate healing. Theralase offers clinical research, training, marketing support, and technical support to help practitioners treat conditions and get equine athletes back in competition more quickly. Studies show Theralase laser therapy can reduce inflammation and pain and speed recovery for injuries like tendon strains, improving outcomes for equine veterinary practices and owners.
Theralase designs, develops, and manufactures patented superpulsed laser technology for biostimulative applications in the human, equine, and companion animal markets. Their laser technology is safe and effective for treating pain, inflammation, and other conditions by promoting cellular regeneration and rebalancing sodium-potassium pathways. Over 3,000 clinical studies and testimonials from medical practitioners have proven the effectiveness of Theralase's laser therapy systems.
Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.
Theralase announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of this technology through strategic partnerships to develop sterilization applications using its low-cost and
Theralase Technologies announced that its Photo Dynamic Compound (PDC) technology was proven effective in destroying drug-resistant Staphylococcus aureus bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections cause difficult to treat invasive infections in 25% of those infected. Theralase's PDCs achieved an 8 log or 99.999999% kill rate of MRSA in laboratory testing, comparable to complete sterilization. The PDCs maintained sterilizing activity in low oxygen conditions, demonstrating potential applications for destroying other deadly organisms that thrive in low oxygen. Theralase is pursuing early commercialization of the PDC technology through strategic partnerships for sterilization applications.
This meta-analysis reviewed 22 randomized controlled trials involving 1014 patients to determine the effectiveness of low-level laser therapy (LLLT) for pain relief in various joint areas. The average methodological quality score of the trials was 7.96 out of 10. The analysis found that 11 trials reported positive effects of LLLT for pain relief while 11 reported negative effects. However, when pooling the results, the mean weighted difference in pain reduction on a visual analogue scale was 13.96 mm in favor of the active LLLT groups, indicating LLLT provides statistically significant pain relief for joints. Restricting the analysis to trials using energy doses within previously suggested therapeutic windows produced even greater mean pain relief of 19.88-21
Theralase Technologies Inc. announced a non-brokered private placement to raise up to $500,000 CAD by issuing units consisting of shares and warrants at $0.25 per unit. Proceeds will support small animal cancer trials, research on photodynamic compounds, expansion of laser sales and marketing in the US, and commercialization of a new therapeutic laser. Theralase designs and markets patented superpulsed laser technology for biostimulation, biodestruction, pain treatment, and tissue regeneration in humans and animals.
Theralase Technologies Inc. announced that it has signed an exclusive distribution agreement with Chengdu Disi Industrial Co. Ltd. to distribute Theralase products in mainland China. Under the terms, Chengdu Disi will market, sell, and provide support for Theralase lasers in China, and Theralase will train Chengdu Disi's personnel. Sales estimates for the first year are planned to exceed $1 million USD. The President of Chengdu Disi stated they were impressed by Theralase's technology and are confident they can successfully promote the brand in China.
This randomized, placebo-controlled clinical trial evaluated low-level laser therapy (LLLT) for treating chronic knee pain in 126 patients. Patients received 12 treatments over 4 weeks with a therapeutic laser system or sham laser plus standardized chiropractic techniques. The primary outcome was pain level measured by the visual analog scale (VAS). Results showed significant pain relief and osteoarthritic improvements in the therapeutic laser group compared to the sham laser group, demonstrating LLLT's effectiveness for treating chronic knee pain.
The document is a quarterly newsletter from Theralase providing updates on their two divisions - Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). It discusses upcoming webinars and seminars, corporate updates including the creation of two operating divisions and identification of bladder cancer as the first clinical target for PDT. It also summarizes partnerships, financing activities, and research progress, including the selection of a leading anti-cancer drug candidate and outlining plans for commercialization and growth.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase complies with FDA, Health Canada, CE, ISO-13485 and CSA-601 regulatory approvals to ensure efficacy, safety and quality in manufacture. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
Theralase Technologies Inc. announced its year-end 2011 financial results, reporting stable total revenues of $2,027,058 compared to 2010. Selling expenses increased 55% due to expansion efforts in the US market, while administrative expenses decreased 17%. Research and development costs rose 26% to advance laser and cancer/bacteria destruction technologies. The net loss was $1,453,974 including non-cash expenses, compared to a 2010 net loss of $1,168,350. Subsequent to year-end, Theralase completed a private placement for gross proceeds of $750,000.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com 1-866-843-5273
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
BBB and BCF
control the entry of compounds into the brain and
regulate brain homeostasis.
restricts access to brain cells of blood–borne compounds and
facilitates nutrients essential for normal metabolism to reach brain cells
This presentation gives information on the pharmacology of Prostaglandins, Thromboxanes and Leukotrienes i.e. Eicosanoids. Eicosanoids are signaling molecules derived from polyunsaturated fatty acids like arachidonic acid. They are involved in complex control over inflammation, immunity, and the central nervous system. Eicosanoids are synthesized through the enzymatic oxidation of fatty acids by cyclooxygenase and lipoxygenase enzymes. They have short half-lives and act locally through autocrine and paracrine signaling.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
- Video recording of this lecture in English language: https://youtu.be/RvdYsTzgQq8
- Video recording of this lecture in Arabic language: https://youtu.be/ECILGWtgZko
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) CosmeticsMuskanShingari
Acne is a common skin condition that occurs when hair follicles become clogged with oil and dead skin cells. It typically manifests as pimples, blackheads, or whiteheads, often on the face, chest, shoulders, or back. Acne can range from mild to severe and may cause emotional distress and scarring in some cases.
**Causes:**
1. **Excess Oil Production:** Hormonal changes during adolescence or certain times in adulthood can increase sebum (oil) production, leading to clogged pores.
2. **Clogged Pores:** When dead skin cells and oil block hair follicles, bacteria (usually Propionibacterium acnes) can thrive, causing inflammation and acne lesions.
3. **Hormonal Factors:** Fluctuations in hormone levels, such as during puberty, menstrual cycles, pregnancy, or certain medical conditions, can contribute to acne.
4. **Genetics:** A family history of acne can increase the likelihood of developing the condition.
**Types of Acne:**
- **Whiteheads:** Closed plugged pores.
- **Blackheads:** Open plugged pores with a dark surface.
- **Papules:** Small red, tender bumps.
- **Pustules:** Pimples with pus at their tips.
- **Nodules:** Large, solid, painful lumps beneath the surface.
- **Cysts:** Painful, pus-filled lumps beneath the surface that can cause scarring.
**Treatment:**
Treatment depends on the severity and type of acne but may include:
- **Topical Treatments:** Such as benzoyl peroxide, salicylic acid, or retinoids to reduce bacteria and unclog pores.
- **Oral Medications:** Antibiotics or oral contraceptives for hormonal acne.
- **Procedures:** Such as chemical peels, extraction of comedones, or light therapy for more severe cases.
**Prevention and Management:**
- **Cleanse:** Regularly wash skin with a gentle cleanser.
- **Moisturize:** Use non-comedogenic moisturizers to keep skin hydrated without clogging pores.
- **Avoid Irritants:** Such as harsh cosmetics or excessive scrubbing.
- **Sun Protection:** Use sunscreen to prevent exacerbation of acne scars and inflammation.
Acne treatment can take time, and consistency in skincare routines and treatments is crucial. Consulting a dermatologist can help tailor a treatment plan that suits individual needs and reduces the risk of scarring or long-term skin damage.
Gene therapy can be broadly defined as the transfer of genetic material to cure a disease or at least to improve the clinical status of a patient.
One of the basic concepts of gene therapy is to transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells.
Safe methods have been devised to do this, using several viral and non-viral vectors.
In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
The biggest hurdle faced by medical research in gene therapy is the availability of effective gene-carrying vectors that meet all of the following criteria:
Protection of transgene or genetic cargo from degradative action of systemic and endonucleases,
Delivery of genetic material to the target site, i.e., either cell cytoplasm or nucleus,
Low potential of triggering unwanted immune responses or genotoxicity,
Economical and feasible availability for patients .
Viruses are naturally evolved vehicles that efficiently transfer their genes into host cells.
Choice of viral vector is dependent on gene transfer efficiency, capacity to carry foreign genes, toxicity, stability, immune responses towards viral antigens and potential viral recombination.
There are a wide variety of vectors used to deliver DNA or oligo nucleotides into mammalian cells, either in vitro or in vivo.
The most common vector system based on retroviruses, adenoviruses, herpes simplex viruses, adeno associated viruses.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
As the world population is aging, Health tourism has become vitally important and will be increased day by day. Because
of the availability of quality health services and more favorable prices as well as to shorten the waiting list for medical
services regionally and internationally. There are some aspects of managing and doing marketing activities in order for
medical tourism to be feasible, in a region called as clustering in a region with main stakeholders groups includes Health
providers, Tourism cluster, etc. There are some related and affecting factors to be considered for the feasibility of medical
tourism within this study such as competitiveness, clustering, Entrepreneurship, SMEs. One of the growth phenomenon
is Health tourism in the city of Izmir and Turkey. The model of five competitive forces of Porter and The Diamond model
that is an economical model that shows the four main factors that affect the competitiveness of a nation and its industries
in this study. The short literature of medical tourism and regional clustering have been mentioned.
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Semi Quantitative Assessment of Inducible NO Synthase am
1. 13/12/2011
Semi -Quantitative Assessment of Inducible NO Synthase in an Acute Inflammation Model
Yumi Moriyama1, Jamie Fong 2 , Arkady Mandel 2 , Margarete K. Akens 3 , Lothar Lilge 1,4
1 Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada, 2 Theralase Inc. Toronto, Canada, 3 Sunnybrook and Women’s College Health Centre., Toronto, Canada 4 Medical Biophysics, University of Toronto, Toronto, Canada
Abstract: Methodology TABLE. Comparison of Sum of Integral of BLI as a Function of
Results
While various mechanisms of action for Low Level Ages in Different LLLT Exposures
Laser Therapy have been proposed, it is evident that 30 transgenic iNOS-luc ( FVB/N-Tg) mice Control
the photon energy delivered to the tissue is (n=10) and Treated (n=30) startified as young < Histological analysis (l=635nm) Groups < 15 week 15-32 weeks > 1year P-value
insufficient as an energy source for any biological 15 weeks versus old > 1 year.
outcome and needs to be augmented by biological Control 9.97 – 3.7 5.65 – 4.7 3.42-1.43 0.021*
processes to improve ATP production or similar. M 635 1.57 – 3.9 3.28 – 4.3 15.2-8.9 0.02*
While in the short, high quantum energy range of F 660 2.88 – 4.9 5.18 – 5.6 0.290
T
LLLT, direct photochemical activation is feasible,
Luciferase Gene From
American Firefly P. Pyrallis 690 2.70 – 4.0 1.44 – 2.4 0.03*
energies at longer NIR wavelengths are typically 785 4.4 -4.2 0.64
insufficient for the majority of photochemical •luciferin + ATP → luciferyl adenylate + PPi 808 3.62-1.2 0.84
PBS [5h] No-LLLT [5h] LLLT [5h]
processes. However, other photophysical processes 905 CW 3.66 – 5.15 6.15 – 3.1 9.21-2.84 0.745
Semi-quantifiable differences in the macrophages and other invading
can lead to activation of the immune system, even by •luciferyl adenylate + O2 → oxyluciferin + AMP + LIGHT cell within the synovial space are evident with more cells seen for 905 PW 15.45 – 5.1 6.61 – 4.1 0.021*
short, transient, thermal effects. Monitoring immune reduced iNOS BLI signal and late time to maximum BLI counts.
modulation effects due to LLLT can become a very Injection of Zymosan A: (yeast cell wall) in PBS P values considered statistically significant are represented
powerful method to understand underlying 12000
with asterisk (*).
mechanisms. NO is a powerful modulator for the Laser irradiation: control
immune system and inducible NO synthase (iNOs) a 10000 635 Discussion
15 min after injection
BLI counts[photons/sec]
785
direct surrogate for its activity. Exploiting Wavelengths: 635nm (n=5) 8000 808
bioluminescence when the luciferase gene is placed 905 Laser therapy 15 minutes post- induction of inflammation
660nm (n=5) 6000
resulted in less recruitment of inflammatory cells to the site,
within the promoter region of iNOs permits the
temporal monitoring of iNOs expression. In an acute
785nm (n=4) 4000 possibly by altering the mechanism of cell attachment by NO
model of inflammation in the murine knee joint it 808nm (n=5)
2000
was shown that a single treatment of 50mW/cm2 905nm (n=11) LLLT increased the expression of iNOS per cell with particular
irradiance of a pulsed NIR light (905nm, 200nsec), 0 PW 905 also showing an earlier time to peak (~5 hrs)
0 5 10 15 20 25 30
with 14mW power and 5J/cm2 radiant exposure, Irradiance: 50 mW cm-2 time[h]
(0.28cm2 spot size), low duty cycle, was most LLLT of 635nm leads to upregulation of iNOS expression, in
radiant power: 5J cm-2 young animals but not as effectively as the longer wavelengths
effective in modulating iNOs expression, showing a iNOS related BLI signal as function of time post Zymosan A
rapid onset. Histology showed an inverse correlation administration for a subset of mice. Average and stdev for n=4, young It seems that iNOS expression is playing a role in the anti-
mice at , 15 weeks only. (from Moriyama Y. et. al. Photochem.
of inflammatory cell concentration in the synovium Photobiol. 2005, 81:1351-1365
inflammatory mechanisms of LLLT.
and integrated bioluminescence signal over the first Longer wavelength appear more effective in older animals.
24hrs of inflammation induction. These results
suggest that high iNOs expression may play a critical
role in the anti-inflammatory mechanisms of LLLT
expression post inflammation may prevent
conversion of an acute inflammation into a chronic
one.
Luciferin injected and bioluminescence images Limitations
See also: Moriyama, Y., Nguyen, J., Akens, M., acquired
The study was executed over multiple years with various students
Moriyama, E., Lilge, L. 2009. Lasers in Surgery and an technical staff performing the breading and genotyping and the
Medicine. 41:227-231. experiments. Variability in determination of homozygous versus
heterozygous state are small, however, success rates in Zymosan
A and Luciferin administration can not be excluded. Unfortunately
we could not randomize the treatment protocols over the
Action spectra of LLLT on iNOS BLI signal. Solid symbols: animals <15 duration of these experiments. The number N of animals is still
weeks. Open symbols: animals >15 weeks so younger than 8 months. low.
Gray symbols: data from Ref. [13], with experiments executed in mice
older than 1 year (signal corrected for homozygote vs. heterozygote
used here). Triangles (~) refer to 905 nm in pulsed wave (PW) mode.
Standard deviations are listed in Table I.
Acknowledgement
The authors with to express their gratitude to Drs. E. Moriyama, R.
t=0h t=3h t=5h t=7h t=9h t=24h Weersink, and Miss J. Nguyen for their support of these studies.
Funding was provided by Ontario Centres of Excellence, Photonics
Research Ontario and Theralase Inc.
1